ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 570,20
-0,77%
Dow Jones
38 834,86
0,15%
DAX
18 067,91
-0,31%
Brent Oil
84,695
-0,11%
Bitcoin
64 838,80
-0,46%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Inovio Pharmaceuticals Inc New (INO)

  7. Inovio Pharmaceuticals Inc New (INO) Actualités

INO

Inovio Pharmaceuticals (INO)

Inovio Pharmaceuticals Inc New
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:INO
DateHeureSourceTitreSymboleSociété
04/06/202414h00PR Newswire (US)INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.NASDAQ:INOInovio Pharmaceuticals Inc New
31/05/202422h48PR Newswire (US)INOVIO Reports Inducement Grants Under Inducement PlanNASDAQ:INOInovio Pharmaceuticals Inc New
28/05/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INOInovio Pharmaceuticals Inc New
22/05/202422h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INOInovio Pharmaceuticals Inc New
13/05/202422h05PR Newswire (US)INOVIO Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:INOInovio Pharmaceuticals Inc New
13/05/202422h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INOInovio Pharmaceuticals Inc New
29/04/202414h00PR Newswire (US)INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024NASDAQ:INOInovio Pharmaceuticals Inc New
29/04/202414h00PR Newswire (US)INOVIO to Participate in Upcoming Investor Conferences in MayNASDAQ:INOInovio Pharmaceuticals Inc New
16/04/202400h39PR Newswire (US)INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:INOInovio Pharmaceuticals Inc New
26/03/202423h28PR Newswire (US)INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn MedicineNASDAQ:INOInovio Pharmaceuticals Inc New
06/03/202422h05PR Newswire (US)INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsNASDAQ:INOInovio Pharmaceuticals Inc New
06/03/202413h00PR Newswire (US)Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:INOInovio Pharmaceuticals Inc New
06/03/202412h02IH Market NewsU.S. Stock Futures Gain Ahead of Economic Insights; Oil Prices ClimbNASDAQ:INOInovio Pharmaceuticals Inc New
21/02/202414h00PR Newswire (US)INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024NASDAQ:INOInovio Pharmaceuticals Inc New
07/02/202417h46PR Newswire (US)INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:INOInovio Pharmaceuticals Inc New
02/02/202414h00PR Newswire (US)INOVIO Reports Inducement Grant Under Inducement PlanNASDAQ:INOInovio Pharmaceuticals Inc New
01/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:INOInovio Pharmaceuticals Inc New
26/01/202422h01Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:INOInovio Pharmaceuticals Inc New
23/01/202414h00PR Newswire (US)INOVIO Announces Effective Date of 1-for-12 Reverse Stock SplitNASDAQ:INOInovio Pharmaceuticals Inc New
22/01/202414h00PR Newswire (US)INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion LeaderNASDAQ:INOInovio Pharmaceuticals Inc New
04/01/202414h00PR Newswire (US)INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)NASDAQ:INOInovio Pharmaceuticals Inc New
03/01/202414h00PR Newswire (US)INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval ProgramNASDAQ:INOInovio Pharmaceuticals Inc New
28/11/202322h05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:INOInovio Pharmaceuticals Inc New
17/11/202322h00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:INOInovio Pharmaceuticals Inc New
09/11/202322h35Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:INOInovio Pharmaceuticals Inc New
09/11/202322h05PR Newswire (US)INOVIO Reports Third Quarter 2023 Financial Results and Operational HighlightsNASDAQ:INOInovio Pharmaceuticals Inc New
26/10/202314h00PR Newswire (US)INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023NASDAQ:INOInovio Pharmaceuticals Inc New
10/10/202316h51Dow Jones NewsInovio Shares Rise 8% After FDA Feedback for INO-3107NASDAQ:INOInovio Pharmaceuticals Inc New
10/10/202314h00PR Newswire (US)INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval ProgramNASDAQ:INOInovio Pharmaceuticals Inc New
28/09/202301h39PR Newswire (US)Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 MillionNASDAQ:INOInovio Pharmaceuticals Inc New
 Showing the most relevant articles for your search:NASDAQ:INO

Dernières Valeurs Consultées

KUCN
YOPUSDT
YOP
LSE
47UJ
Sigma Fin.3.755
LATK
LOOKSUSDT
LooksRare Token
LSE
38OG
Bk.amercia 7.00
ASX
MMKT
BetaShares Capital
AMEX
IYF
iShares US Financials
NYSE
HSP
Hospira
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés